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Hepatitis Research Center, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei 10002, TaiwanHepatitis B virus infection is a global health problem. Worldwide, about 360 million people are chronically infected with
the virus. They continue to spread the virus to others and are themselves at risk of chronic liver diseases and hepatocellular
carcinoma. The infection can now be treated by antivirals or interferons and the transmission route can be interrupted.
Nevertheless, the most eﬀective means is to immunize all susceptible individuals, especially young children, with safe
and eﬃcacious vaccines. The combined eﬀorts of vaccination, eﬀective treatment and interruption of transmission make
elimination of the infection plausible and may eventually lead to eradication of the virus. Because hepatitis B vaccination
has a key role in the control of hepatitis B, properties of this vaccine, its eﬀectiveness in pre-exposure and post-exposure
settings, duration of protection after vaccination and the need of booster doses are discussed. Mass hepatitis B vaccination
in children decreases the carriage of the virus, and the diseases associated with acute and chronic infection, including hepa-
tocellular carcinoma. Challenges that need to be solved to expand mass vaccination, and the strategies towards elimination
and eventual eradication of hepatitis B in the world are also discussed.
 2009 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
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Hepatitis B virus (HBV) infection is one of the most
common and important human viral infections. The
infection can cause acute and chronic liver diseases,
ranging from fulminant hepatitis to cirrhosis and even-
tually hepatocellular carcinoma (HCC) [1]. Worldwide,
as many as 360 million people are chronically infected
with HBV, and 1 million deaths are attributed to its
infection [2]. Hence, control of HBV infection is extre-
mely important. Strategies to ﬁght against the infection
comprise interrupting the route of transmission, treating0168-8278/$36.00  2009 European Association for the Study of the Liver.
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E-mail address: chends@ntu.edu.tw.chronically infected patients as well as treating suscepti-
ble individuals with immunoproplylaxis [3].
As we enter the ﬁfth decade of the ﬁght against HBV
following its discovery, advances in vaccine develop-
ment/implementation and antiviral therapies have shed
more light on the elimination and eradication of HBV
infection [4]. Although current antiviral treatments
using pegylated interferons or nucleos(t)ide analogs are
eﬀective for chronic hepatitis B, chronic HBV carriage
is not easy to eliminate, as shown by the frequent persis-
tence of hepatitis B surface antigen (HBsAg) in those
who have responded well to the available treatments
[5]. On the other hand, from the very beginning, the hep-
atitis B vaccine has proved to prevent HBV infection
eﬀectively [6,7]. Vaccination of infants against hepatitis
B, especially those born to HBV carrier mothers [8] is
the most eﬀective way to control the spread of HBV.
And thus, universal infant vaccination will be the keyPublished by Elsevier B.V. All rights reserved.
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tis B. Elimination and eradication of hepatitis B require
long-term commitment all over the world to continue
the vaccination as well as interrupting the routes of
transmission, treating the chronic HBV carriers, so that
the infection is completely stopped. Because of the
important role of hepatitis B vaccine in the control of
hepatitis B, the current status of hepatitis B vaccination
is reviewed.2. The hepatitis B vaccine
In 1982, two hepatitis B vaccines from France and the
United States were licensed. They were subunit vaccines
containing 22-nm HBsAg particles made from plasma of
chronic HBsAg carriers. The preparations undergo vig-
orous inactivation steps and are highly puriﬁed, and alu-
minum hydroxide is added as an adjuvant. The vaccine
is preserved with thimerosal.
Millions of doses of the ﬁrst-generation plasma-
derived vaccines have been used, and the eﬀectiveness
and safety records are excellent. However, concerns on
the safety of human blood products always exist, espe-
cially after the discovery of human immunodeﬁciency
virus (HIV) in the early 80’s [9]. Meanwhile, recombi-
nant DNA technology has matured to such an extent
that it has led to the satisfactory production of HBsAg
in the yeast, Saccharomyces cerevisiae. The yeast-derived
HBsAg was then used for vaccination, also showing
excellent eﬀectiveness and safety. Nowadays, it has gen-
erally replaced plasma-derived vaccines. Recombinant
DNA vaccines can also be produced by inserting plas-
mids containing HBsAg genes into mammalian cells.
Although the current vaccines are highly eﬀective
with a rate of 94–98% in protecting from chronic HBV
infection for at least 20 years [10], they are far from per-
fect. There are still some populations in which the non-
response rate is substantial, such as the elderly, smokers,
obese individuals, those with chronic hepatic or chronic
renal diseases. This resulted in more immunogenic hep-
atitis B vaccines being developed by incorporating HBV
DNA sequences coding for pre-S1 and pre-S2 protein
into the vector used for recombinant DNA technology
in manufacture [11,12]. Additionally, improvement of
the adjuvants to make the vaccine more immunogenic
has also been tried [13].
To decrease the number of injections that are needed
in routine immunizations to infants, combination vac-
cines containing HBsAg have been produced. The com-
ponents of these combination vaccines include
diphtheria, tetanus toxoids and acellular pertussis or
whole-cell pertussis; Hemophilus inﬂuenzae type b; inac-
tivated poliovirus; and hepatitis A virus. Any combina-
tion vaccine should demonstrate adequate eﬃcacy as
compared with individual vaccines. Pentavalent [14,15]and hexavalent [16] combination vaccines have been
developed successfully recently. The combination vac-
cine not only decreases the number of injections but also
increases the coverage rates of vaccination [17]. The
development of hepatitis B vaccines and the public
health strategy of hepatitis B vaccination have been
reviewed recently [18,19].
The vaccine should be kept at 2–8 C and should
never be frozen. It is relatively heat-stable [20], the
immunogenicity does not change when the vaccine is
stored for up to one month at ambient temperature
[21] or even at tropical temperature [22]. The heat stabil-
ity helps greatly to deliver the vaccine in places where
refrigeration is not available.3. Eﬀectiveness of vaccination
Hepatitis B vaccination is highly eﬀective in both pre-
exposure and post-exposure prophylaxis. Antibody to
HBsAg (anti-HBs) is neutralizing and serum levels of
10 mIU/mL are protective.
3.1. Pre-exposure settings
The most extensively studied populations for pre-
exposure prophylaxis are homosexuals and health-care
workers. Randomized, double blind, placebo-controlled
clinical trials have demonstrated a protective eﬃcacy of
80–88% in male homosexuals [6,23–25]. In health-care
workers, hepatitis B vaccine appears to be eﬃcacious
[26], especially in high-risk health-care workers, such
as staﬀ of renal hemodialysis units [27–29]. Patients with
end-stage renal disease (ESRD) on hemodialysis are also
protected by the vaccine [29–31], however, not all stud-
ies demonstrated that ESRD patients receiving hemodi-
alysis beneﬁt from hepatitis B vaccination [32,33]. Part
of the reason may be the lower immune response to
the vaccine in these patients. The poor response is attrib-
uted to malnutrition, uremia and the generalized immu-
nosuppression state in this population. Patients with
serum creatinine 4 mg/dL have been shown to respond
less eﬀectively after hepatitis B vaccination (86% vs.
37%) [34]. Those with glomerular ﬁltration rate
<10 mL/min, >60 years of age, and diabetes mellitus
are less likely to seroconvert after immunization [35].
Eﬃcient hemodialysis improves the response to hepatitis
B vaccine [36,37]. A coexisting hepatitis C virus infection
may reduce the eﬀectiveness of the vaccine in patients on
maintenance hemodialysis [38]. The poor response to
hepatitis B vaccine can be rescued with reinforced vacci-
nation protocols by increasing the dose or number of the
vaccines [39,40]. Changing the route of vaccine adminis-
tration from intramuscular to intradermal injections has
also been claimed to improve the immunogenicity and
may be cost-eﬀective [41,42]. However, other studies
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dermal or intramuscular injections are almost the same,
although the dose of hepatitis B vaccine can be reduced
[43,44]. Because the dosage and number of intradermal
injections diﬀered in diﬀerent studies, and how long
the anti-HBs induced by the inoculation will last is
unclear, a ﬁrm conclusion cannot be drawn.
For subjects infected with HIV, the responses after
hepatitis B vaccination are suboptimal, either to
plasma-derived vaccines or recombinant vaccines [45–
48, reviewed in 49]. Based on a total of 447 subjects, rel-
atively adequate CD4+ T-cells of 500/mm3 and lower
HIV viral loads of 1000 copies/mL ensure immune
responses to hepatitis B vaccine [49]. Nevertheless, those
whose CD4+ T-cell counts and HIV viral loads are less
favorable should not be denied the vaccination. A rein-
forced protocol as that used for those with other types of
immune suppression can be employed and post-vaccina-
tion monitoring can also be conducted [49]. The
response to hepatitis B vaccine in patients with acquired
immune deﬁciency syndrome (AIDS) treated with highly
active anti-retroviral therapy (HAART) may recuperate
in adults [49,50] and children [51].
Patients with chronic liver disease also have subopti-
mal responses to hepatitis B vaccination. In addition to
age and genetic predisposition, the severity of liver dis-
ease and the underlying etiology also play a critical role.
For example, chronic alcoholics have inadequate
responses to the hepatitis B vaccine, especially when
the liver disease is overt [52,53]. In patients with non-
hepatitis B chronic liver disease who receive liver trans-
plant, the anti-HBs seroconversion rate is low after hep-
atitis B vaccination [54–56]. The responses in those
transplanted for HBV-related cirrhosis are especially
poor, even after a reinforced triple course of vaccination
[57] or a double course of recombinant vaccine contain-
ing pre-S1, pre-S2 and S protein [58], only few patients
have adequate levels of anti-HBs.
Hepatitis B active immunization after liver trans-
plant, if responsive in the transplant recipient, can pre-
vent HBV recurrence following withdrawal of hepatitis
B immune globulin (HBIG) [59]. Protection was espe-
cially evident in Taiwanese pediatric patients in a recent
study [60]. In the study, all the 60 patients had received
hepatitis B vaccination previously in a national infant
hepatitis B vaccination program [61]. The results imply
that in the future, after universal infant vaccination
against HBV is widely implemented, pre-transplant
booster with HBV vaccines will very likely prevent the
occurrence of post-transplant de novo or recurrent
HBV infection.
Responses to hepatitis B vaccine are also low in the
recipients of renal transplant [62,63]. Increased dose
and intradermal route of vaccination have also been
tried to improve the immunogenicity with some success
[64]. Because age of the patient has been shown tocorrelate with immune response to hepatitis B vaccine
in patients with ESRD [65], and the immunogenicity is
much higher if the vaccine is given before renal trans-
plantation [66], hepatitis B vaccination should be given
as early as possible for patients with ESRD, preferably
before renal transplantation.
The poor response to hepatitis B vaccine can be
improved by a diﬀerent route of vaccine administration
(see above), increased dose and frequency of vaccination
[39,40,67,68]. The adjuvant can also be improved. A new
adjuvant systemcontaining3-deacylatedmonophosphoryl
lipid A and a natural saponin molecule fromQuillaja sap-
onaria in an oil/water emulsion has been claimed to yield a
better immune response of the vaccine, although the pro-
tective antibody declines rapidly [69]. Unfortunately, the
results could not be reproduced in another study [70].
Another approach is to use the biologically active
molecules like granulocyte macrophage colony-stimulat-
ing factor as the adjuvant. A meta-analysis favors a sig-
niﬁcant eﬀect in the antibody response rate and the
achievement of an earlier seroconversion to the vaccine
[71]. Other approaches include hepatitis B DNA vacci-
nation with plasmid DNA encoding HBsAg [72], or
administration of HBsAg-pulsed blood dendritic cells
[73], preliminary results in hepatitis B vaccine non-
responders showed some promising results. More stud-
ies are needed to conﬁrm these ﬁndings. The use of
DNA immunization with oligodeoxynucleotides con-
taining CpG motifs attempting to enhance the immune
response, although successful in mice, was not eﬀective
in chimpanzees [74].
3.2. Post-exposure settings
The most thoroughly studied population for post-
exposure prophylaxis is infants born to hepatitis B e
antigen (HBeAg)-positive HBsAg carrier mothers. To
bridge the gap between exposure to HBV and active pro-
duction of anti-HBs induced by the hepatitis B vaccine,
HBIG is given as soon as possible in these newborns no
later than 24 h after birth. The eﬃcacy of protecting
from chronic HBV infection in these individuals is
>90% [8,75–80]. If HBIG is skipped, the eﬃcacy is
slightly lower, but can still be >83% [78,80–83]. These
ﬁndings form the basis in support for the use of vaccine
alone in countries where pregnant women are not
screened for HBsAg and HBeAg [84]. Another impor-
tant issue is the timely birth dose which should be given
within 24 h after delivery, because a delay in this initial
dose has been shown to lead to an increased risk of
infection in children whose mothers are HBsAg carriers
[85,86]. The heat stability of hepatitis B vaccines renders
the administration of a timely birth dose feasible also in
rural and remote areas [21,22,87,88].
Although HBeAg is a good marker of infectivity for
us to judge whether to give or to skip administration
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carriers [61], despite hepatitis B vaccination, about 3%
of infants born to HBeAg-negative HBsAg carrier
mothers will still become persistently infected [89], indi-
cating that deﬁning infectivity by HBeAg in HBsAg car-
riers is not perfect. Actually, measurements of serum
HBV DNA levels of HBsAg carrier mothers have been
explored for the prediction of perinatal mother-to-infant
transmission after immunoprophylaxis [90–93]. How-
ever, the results of these studies were confounded by
hepatitis B immunoprophylaxis in the infants, and the
roles of maternal serum HBV DNA and HBeAg in pre-
dicting infectivity were diﬃcult to compare.
In a cohort of 773 Taiwanese HBsAg-positive moth-
ers and their infants in 1972–1980, it was documented
that the maternal serum HBV DNA level is a stronger
independent predictor of the infant’s persistent HBV
infection than HBeAg [94]. In 22 HBeAg-positive
HBsAg carrier women with undetectable serum HBV
DNA, only 1(4.5%) of their infants became HBsAg car-
riers, in contrast to 82 HBV DNA-positive women’s
infants in whom 53 (64.6%) became carriers. In 107
HBeAg-negative women, the persistent HBV infection
in infants of 99 HBV DNA-negative and 8 HBV
DNA-positive mothers was 5 (5.1%) and 3 (37.5%),
respectively. The study also showed a linear relationship
between maternal viral load and the likelihood of persis-
tent HBV infection in their infants [94]. Hence, to decide
whether HBIG should be used in newborns of HBsAg
carrier mothers, serum HBV DNA rather than HBeAg
appears to be more logical. However, further studies
are needed [92].
Because maternal hepatitis B viral load is the most
critical factor in causing HBV infection in the newborns
even after passive-active immunoprophylaxis, by anal-
ogy with the situation in HIV infection [95], lowering
the maternal viral load by antiviral therapy may reduce
perinatal HBV infection. Indeed, in a pilot study [96],
eight highly viremic HBsAg carrier mothers (serum
HBV DNA 1.2  109 geq/ml) received lamivudine
(150 mg per day) in the last month of pregnancy from
week 34 on, one of 8 (12.5%) immunized infants became
chronically infected. In the untreated historical controls,
the chronic infection occurred in 7 of 25 (28%) children.
Nevertheless, the data investigating whether addition of
anti-HBV antivirals to near-term pregnant HBsAg car-
rier women will yield additional decrease of perinatal
HBV infection are limited, and thus needs to be
addressed further with randomized control trials. In
addition, the issues of cost as well as safety in the moth-
ers and newborns also require careful consideration.
Preterm infants have decreased antibody response to
hepatitis B vaccine [97], especially those with low birth
weights (<1800 gm) [98,99] or premature gestation ages
(<34 weeks) [99]. It has been recommended to defer
the ﬁrst dose of the vaccine in HBsAg-negative mother’sinfants weighing <2000 gm until they reach 2000 gm, or
alternatively, until one month old [100,101].
3.3. Duration of protection and the need of booster doses
Vaccine-induced anti-HBs declines rapidly in the ﬁrst
year and then more gradually (reviewed in [102]). As
time passes, the anti-HBs frequently becomes undetect-
able. Nevertheless, the vaccine-induced immunologic
memory is maintained for at least 12 years despite the
decline of anti-HBs [103]. Although, by testing humoral
and cellular immunological parameters after a vaccine
booster, we found a substantial proportion of fully vac-
cinated adolescents seem to lose immune memory con-
ferred by hepatitis B vaccine given in infancy 15–18
years previously [104], whether these ﬁndings represent
susceptibility to HBV infection remains to be seen.
Actually, a booster vaccination is not needed for at least
20 years in Taiwan, because surveillance did not reveal
any increase of acute hepatitis B [105] or chronic HBV
infection [10] in adolescents vaccinated 20 years ago.
For endemic areas like Taiwan where the primary goal
of hepatitis B immunization is to prevent hepatitis B
chronic carriage in infancy [61], even if the immunity
conferred by the vaccine given in early childhood disap-
pears, when the unprotected vaccine contract HBV
infection in adulthood, the risk of becoming HBsAg car-
riers is far lower [106]. In this case, the primary goal has
already been achieved then. A global universal infant
immunization will postpone HBV infection in any given
population to an older age when HBV infection will
result in much less chronic HBsAg carriage worldwide.
This will be a signiﬁcant step towards the eradication
of HBV infection. Nonetheless, after chronic HBV infec-
tion is well-controlled, the need of preventing acute hep-
atitis B in young adults will become evident. Therefore
prolonged follow-up and surveillance of the vaccinees
who received immunization in early childhood should
continue. A booster vaccination will be considered only
when the cohort start to have clinically signiﬁcant acute
hepatitis B. So far, in the endemic areas for hepatitis B,
breakthrough HBV infections in the vaccinees who
received the immunization in infancy occur infrequently,
ranging from 0.008% to 0.19% per year (Table 1) [107–
112]. In the rare cases of these breakthrough infections,
they are subclinical and rarely become chronic.4. Hepatitis B mass vaccination
After the hepatitis B vaccine became available, it was
found that targeting at populations at risk of HBV
infection, such as homosexuals, sex workers, drug abus-
ers or teenagers was not easy [113]. On the other hand,
universal vaccination against HBV in newborns was
found to be easier and cost-eﬀective [114,115].
Table 1
Breakthrough hepatitis B virus infections in the vaccinees who received hepatitis B immunization in childhood.
Author [Ref.]/year/country No. of subjects
studied
No. with HBV
infectiona
Observation
period (years)
Average annual
incidence (%)
Lin et al. [107]/2003/Taiwan 1200 11 7 0.13
Boxall et al. [108]/2004/UK, Asian 64 1 15.1 0.10
52 1 11.8 0.16
Yuan et al. [109]/2004/China, Hong Kong 88 3 18 0.19
McMahon et al. [110]/2005/US, Alaska 1578 16 15 0.08
Dentinger et al. [111]/2005/US, Alaska 334 6 10 0.18
Zanetti et al. [112]/2005/Italy 1212 1 10.6 0.008
HBV: hepatitis B virus.
a The infections were asymptomatic and rarely became chronic.
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Expanded Program on Immunization (EPI) of infants
has been shown to be feasible and practical
[84,116,117]. As of 2007, according to World Health
Organization (WHO) 71 (89%) of the 193 member states
had initiated a hepatitis B vaccination program. The
global coverage of completing three doses of hepatitis
B vaccine was 65% on average, ranging from 89% in
the American Region to 28% in the Southeast Asian
Region [http://www.who.int/immunization_monitor-
ing/data/en/].
Due to the fact that chronic HBsAg carriage has
been shown to correlate with the age when HBV
infection occurs, the younger the age, the higher
the chronicity [106], and because of the very high
prevalence of chronic HBV infection in Taiwan as
well as the extremely heavy disease burden caused
by HBV [118], a national hepatitis B vaccination
program was launched in 1984 [61], soon after the
hepatitis B vaccines became available. As this is
the earliest nationwide hepatitis B mass vaccination
in the world, much important information can be
obtained from it and I will use Taiwan’s experience
to elucidate some of the issues in this review.
Brieﬂy, pregnant women were screened for HBsAg
and then HBeAg. If they were positive for HBeAg,
their newborn infants received HBIG immediately
after birth, followed by hepatitis B vaccine givenTable 2
Four diﬀerent strategies of universal hepatitis B immunization in infants.a
Maternal screening Infants receive
Vaccine HBIG
Yes (HBsAg and then HBeAg) Yes HBeAg-positive mothe
Yes (HBsAg only) Yes All HBsAg-positive mo
Yes (HBeAg only) Yes HBeAg-positive mothe
No Yes No
HBsAg: hepatitis B surface antigen.
HBeAg: hepatitis B e antigen.
HBIG: hepatitis B immune globulin.
a Modiﬁed from Chang [120].
b Before 1995.within the ﬁrst week of life. In more than 90% of
infants, the ﬁrst dose was given in the ﬁrst or sec-
ond day after birth. In those carrier mothers who
were negative for HBeAg, the infants receive hepati-
tis B vaccines only, so did infants of non-carrier
mothers. The program was carefully planned and
has been supported strongly by Taiwan’s Govern-
ment [61]. Mass immunization against hepatitis B
is very well accepted by the people and the coverage
rate of vaccination in infants is >96% [10].
Worldwide, there are four diﬀerent strategies of
universal hepatitis B vaccination in newborns
(Table 2). The most simple one is to give the vaccine
to all newborns regardless of the maternal HBV sta-
tus. Because screening of pregnant women is not nec-
essary and HBIG is skipped in newborns, this strategy
incurs the lowest costs. However, the eﬃcacy may be
jeopardized [78,80–83,119]. The most expensive yet
most eﬃcacious strategy is to give hepatitis B vaccine
to all newborns, and to screen the pregnant women
and add on HBIG to the newborns if the mother is
positive for HBsAg, regardless of the HBeAg status.
Each country can choose its own strategy depending
on its own needs after considering epidemiology, dis-
ease burden, readiness of the public health system
and economic constraint. Any approach in implement-
ing hepatitis B vaccination will help to control hepati-
tis B in the country.Eﬃcacy Cost Example
rs’ infants only Higher Higher Taiwan
thers’ infants Highest Highest US
rs’ infants only (2 doses) High Highest Japanb
Modest Low Thailand
Fig. 1. Prevalence of hepatitis B surface antigen (HBsAg) in healthy
children in Taipei from 1984 to 2004 [10]. The mass hepatitis B
vaccination started in July 1984.
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After implementation of the universal hepatitis B vac-
cination in infants, seroepidemiologic studies soon
reveal a steady and remarkable decrease of chronic
HBsAg carrier rate in children, as shown in serial sur-
veys in Taipei City in 1989, 1994, 1999 and 2004
(Fig. 1) [10]. The decrease has been conﬁrmed in other
parts of Taiwan (Table 3). Once hepatitis B vaccination
is implemented in early childhood, there is always an
evident eﬀectiveness of protecting from chronic HBV
infection (Table 3). In less endemic areas, the post-vac-Table 3
Eﬀectiveness of protecting from HBsAg carriage after hepatitis B
immunization.a
Country HBsAg (%) Eﬃcacy (%)
Before After
China, rural 14.6 1.4 90.4
China (Shanghai) 11 0.63 94.3
Egypt (Alexandria) 2.2 0.8 63.6
Gambia 12 0.9 92.5
Indonesia (Lombok) 6.2 1.4 61.1
Italy (Afragola) 13.4 0.9 93.3
Japan (Iwate) 0.9 0.03 96.7
(Shizuoka) 0.3 0.03 90.0
Korea 7.5 0.38 94.9
Malaysia 2.5 0.4 84.0
Micronesia 12 2.9 75.8
Polynesia 6.5 0.7 89.2
Saipan 9 0.5 94.4
Samoa 7 0.5 92.9
Saudi Arabia 6.7 0.3 95.5
Senegal 19 2 89.5
Singapore 4.1 0 100
South Africa 12.8 3.0 76.6
Taiwan (Taipei) 10 0.7 93.0
(Hualien) 9.3 1.9 79.6
(Taichung) 14 1.2 91.4
Thailand 4.3 0.7 83.7
US (Alaska) 16 0 100
a Reference list will be provided on request.cination HBsAg carrier rate can even reach zero, harbin-
gering the elimination and eventual eradication of HBV
in the population.
4.2. Decrease of diseases associated with acute HBV
infection
After universal hepatitis B vaccination in infants, the
mortality rate of fulminant hepatitis in infants decreases
remarkably. In our study, fulminant hepatitis in infants
reduced 70% (from 5.36/105 in pre-vaccination era to
1.71/105 post-vaccination) [121]. In addition, fulminant
hepatitis B in children older than one year of age is then
nearly wiped out [122]. In Italy where HBV is intermedi-
ately endemic and universal vaccination of infants and
adolescents was launched in 1991, besides decrease of
chronic HBV infection, the incidence of acute hepatitis
B decreased 50-fold, from 1/105 in pre-vaccination era
to 0.02/105 post-vaccination [123]. Nevertheless, it was
found that HBV infection through household contacts
of chronic HBsAg carriers, injection drug use, and iatro-
genic procedures still needed to be interrupted to eradi-
cate the residual HBV infection in the country. An
anticipated bonus after universal hepatitis B vaccination
in Italy is the marked decrease of acute hepatitis D infec-
tion [124]. In Singapore, a similar decrease of acute hep-
atitis B was also noted after hepatitis B vaccination
[125].
4.3. Decrease of diseases associated with chronic HBV
infection
After hepatitis B vaccination in South Africa, a hos-
pital-based study clearly demonstrated a sharp decline in
the incidence of HBV-associated membranous nephrop-
athy [126]. Another hospital-based study from China
also revealed that the incidence of HBV-associated glo-
merulonephritis decreased steadily after nationwide hep-
atitis B vaccination program [127].
4.4. Decrease of hepatocellular carcinoma
In endemic areas of chronic HBV infection, HCC is
always prevalent and occurs usually after middle age
[2,118]. If one wants to see the impact of hepatitis B vac-
cination on the occurrence of HCC, one would have to
wait for 4–5 decades after the vaccination. Fortunately,
we found a proxy to serve this purpose. In endemic areas
of HBV, HCC in children can be seen occasionally, and
is almost always related to chronic HBV infection which
was transmitted to the patient from their mothers [128].
To investigate whether or not universal hepatitis B vac-
cination in newborns has impacts on the occurrence of
HCC in Taiwan, we studied the incidence of HCC in
children 6–9 years of age. It declined 4-fold from 0.52/
105 in the cohort born before implementation of the uni-
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after the program [129]. Another study that included
Taiwanese children 0–9 years of age also reached the
same conclusions [130].After some time, the studies were
extended to children of 14 years of age, and the decrease
of HCC was again evident [131,132]. Our most recent
observations in adolescents (up to 19 years old) have
shown that the eﬀect has extended from childhood to
early adulthood (unpublished observations). A cohort
study from Korea suggested that hepatitis B vaccination
in men can reduce the risk of HCC [133]. After large-
scale hepatitis B vaccination, a similar trend of decrease
in the incidence of HCC has also been reported form
Singapore [125], China [134] and Saudi Arabia [135].
However, whether the decrease of HCC in these coun-
tries was associated with hepatitis B vaccination could
not be ascertained, because the decrease was also seen
in adult populations who were not vaccinated.5. Safety and adverse events
Todate,more than one billion doses of plasma-derived
or recombinant DNA vaccines have been used, and the
safety records of the hepatitis B vaccines are excellent.
Besides reactogenicities that include mild fever in 1–6%
of vaccinees and soreness at the injection site in 3–30%,
there is a remote risk of anaphylaxis (1.1 per million
doses) [136]. In addition, the following outcomes have
been claimed to be the adverse reactions after hepatitis
B vaccination, namely, chronic fatigue syndrome, multi-
ple sclerosis, sudden infant death syndrome, rheumatoid
arthritis, leukemia, macrophagic myofasciitis, type I dia-
betes, vasculitis, immune thrombocytopenic purpura,
central retinal vein occlusion, lichenoid, lichen planus,
cutaneous lupus, Guillain–Barre´ syndrome, transverse
myelitis, optic neuritis, ﬂuctuating hearing loss, hair loss,
etc.Manyof themare rare andoccur also in the absence of
hepatitis B vaccination. The causal association of these
disorderswith the vaccination is not established (reviewed
in [137] recently). A similar situation also occurred in
alleged suspicion of ethyl mercury-containing vaccine
preservative – thiomersal in causing adverse reactions.
Actually thiomersal has long been a safe and eﬀective pre-
servative [137]. Nevertheless, to avoid laborious yet
unproductive defence against repeated alleged accusa-
tions, many pharmaceutical companies have avoided
using it in their vaccines. In making decisions, it should
be borne in mind that the beneﬁt of hepatitis B vaccina-
tion far outweighs the alleged adverse reactions.6. Vaccine escape mutants
Under immune pressure of hepatitis B immunization,
especially when HBIG is combined, HBV with muta-tions in the a determinant can be selected [138]. The
most common is a glycine to arginine change at amino-
acid position 145. In Taiwan, the baseline prevalence of
the a mutants was 7.8% in HBsAg carrier children, and
was kept around 20% among HBsAg carrier children in
the ﬁrst 15 years of the universal mass vaccination pro-
gram [139]. In the last 10 years, there has been no steady
increase of the vaccine escape HBV mutants in Taiwan-
ese carrier children who failed in the mass vaccination
program, and there has been no evidence of the spread
of this virus, likely because of the weakness of the
mutant virus [140]. Despite the increased percentage of
surface gene mutants after mass hepatitis B vaccination,
the actual number of children infected with this mutant
is small and is not increasing [139]. The results in Italy
also concurred with the same conclusions [141]. There-
fore, the presence of vaccine escape mutants does not
seem to threaten the ongoing hepatitis B control strate-
gies in Taiwan and Italy, and perhaps, worldwide. Wor-
thy of note is the fact that the current hepatitis B
vaccines can protect chimpanzees from the infection
with this a mutant virus [142]. Hence, the currently
available hepatitis B vaccines can be continued.7. Challenges that need to be solved to expand hepatitis B
mass vaccination
Although the hepatitis B vaccine has been available
since 1982, and more than one billion people have been
vaccinated, there are still many people who are not
immunized. According to WHO, in 2006, 40% of infants
worldwide had not yet received three doses of hepatitis
B vaccine. The causes of failing to oﬀer large-scale hep-
atitis B vaccination in each country are complicated.
7.1. Improving infrastructure of public health delivery
system
In the absence of an eﬀective system of public health
delivery, basic regular immunization for infants is
impossible, not to mention hepatitis B immunization.
Usually such countries are poor and have limited
resources for creating and maintaining regular opera-
tional facilities for public health. The well-trained public
health personnel necessary to carry on the immunization
program are also inadequate or even lacking. And thus,
it is of vital importance to support these countries, so
that vaccinations can be given as much as possible,
including the hepatitis B vaccine. Integration of hepatitis
B vaccination to the EPI will facilitate the vaccination in
children [84,116,117].
Besides the constant endeavors on behalf of govern-
ments and WHO, eﬀorts from non-government organi-
zations are also needed. Among them, Global Alliance
on Vaccines and Immunization (GAVI) is most note-
Fig. 2. Components of hepatitis B virus (HBV) infection and the relation
to eradication of the infection.
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coalition of international organizations, philanthropic
foundations, private sectors including vaccine industry
representatives as well as research and public health
institutions [143]. It targets the world’s poorest countries
to help improve child health by extending the reach and
quality of immunization coverage with strengthened
health services. The hepatitis B vaccine has been
included in the GAVI since 2000. Millions of children
since then have received hepatitis B vaccine through
the help of GAVI. In 2004, the coverage rate was
37.9% in 52 of the 75 counties eligible for GAVI sup-
port. By the end of 2008, 71 countries are expected to
have introduced the hepatitis B vaccine [Hepatitis B.
GAVI Alliance. www.gavialliance.org].
7.2. Public education
The public should be educated about the impor-
tance and necessity of hepatitis B prevention by vac-
cination. In Taiwan, we dedicated a lot of time and
eﬀorts in public education for nearly three years prior
to the implementation of our universal vaccination
program in 1984 [61]. Because of the importance of
giving immunization immediately after birth, young
people, especially women of reproductive age, are tar-
geted for this education. At the same time, education
of medical personnel is also necessary, because iatro-
genic HBV infections are an important mode of HBV
transmission. The key role of education can be seen
in the Italian experience. Despite the success of uni-
versal vaccination against HBV since 1991, household
contacts of HBsAg carriers, injection drug use,
unprotected sexual behaviors and invasive medical
procedures are still evident in transmitting HBV
[123].8. Strategies towards eradication of hepatitis B
As depicted in Fig. 2, HBV infection has three com-
ponents, an infectious source, a susceptible host and
an established route of transmission [3]. Because
humans are the only reservoir of HBV, it is not impos-
sible that a comprehensive control can eventually lead
to the eradication of the virus. To begin with, the exist-
ing HBV carriers can now be treated eﬀectively [5] and
viral load can decrease to undetectable levels, so that
infection does not spread rampantly. However, pro-
longed use of current nucleos(t)ide analogs against
HBV still poses the problem of viral resistance and the
cost of long-term treatment is still high [5]. Another
important strategy is to interrupt the transmission route
which can be reduced after education of the public and
medical personnel as mentioned above although changes
in high-risk human behaviors are often diﬃcult. Themost eﬀective strategy is to immunize all susceptible
individuals with the hepatitis B vaccine, especially chil-
dren [2,3].
In the modern globalized world, international travel
and immigration are frequent, and adoption of children
from HBV high-endemicity countries is not uncommon.
Countries where the incidence of HBV infection is low
should seriously consider shifting their immunization
policy from targeting at-risk population to universal
childhood hepatitis B vaccination [144–146]. Universal
hepatitis B vaccination in childhood can prevent not
only chronic HBV infection in high endemic areas, but
also acute HBV infection in low endemic areas. There-
fore, it should be recommended for all countries, regard-
less of HBV endemicity [147]. The combined eﬀorts of
universal vaccination, antiviral treatment and interrup-
tion of transmission make elimination of HBV infection
plausible and eventually may result in the eradication of
HBV. To reach this goal, all the eﬀorts need to be sup-
ported adequately, and a long-term commitment from
each government, WHO or non-government organiza-
tions is a must. The support should sustain and over-
come the existing backlog of HBV carriers in the
population. The goal of eradicating HBV is plausible,
but every endeavor has to be pursued to make it become
a reality.
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